Prophylactic cranial irradiation in extensive small-cell lung cancer

New England Journal of Medicine

Volumn 357, Issue 7, 2007, Pages 664-672

  Slotman, Ben ^a   Faivre Finn, Corinne ^c   Kramer, Gijs ^b   Rankin, Elaine ^d   Snee, Michael ^e   Hatton, Matthew ^f   Postmus, Pieter ^a   Collette, Laurence ^g   Musat, Elena ^g   Senan, Suresh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Arnhems Radiotherapeutisch Instituut   (Netherlands)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^f WESTON PARK HOSPITAL   (United Kingdom)

^g EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; HEADACHE; HUMAN; LETHARGY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VOMITING;

EID: 34547937885     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa071780     Document Type: Article

References (31)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-44.
2. Seute T, Leffers P, ten Velde GPM, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004;100:801-6.
3. Nugent JL, Bunn PA Jr, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer 1979;44:1885-93.
4. Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-22.
5. Seute T, Leffers P, Wilmink JT, ten Velde GPM, Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006;24:2079-83.
6. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 1992;10:1498-502.
7. Postmus PE, Haaxma-Reiche H, Gregor A, et al. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy: an EORTC phase II study. Radiother Oncol 1998;46:29-32.
8. Postmus PE, Haaxma-Reiche H, Sleijfer DT, Kirkpatrick A, McVie JG, Kleisbauer JP. High dose etoposide for brain metastases of small cell lung cancer: a phase II study. Br J Cancer 1989;59:254-6.
9. Postmus PE, Smit EF, Haaxma-Reiche H, et al. Teniposide for brain metastases of small cell lung cancer: a phase II study. J Clin Oncol 1995;13:660-5.
10. Groen HJM, Smit EF, Haaxma-Reiche H, Postmus PE. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. Eur J Cancer 1993;29A:1696-9.
11. Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole brain radiotherapy - a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000;18:3400-8.
12. Felletti R, Souhami RL, Spiro SG, et al. Social consequences of brain or liver relapse in small cell carcinoma of the bronchus. Radiother Oncol 1985;4:335-9.
13. Hardy J, Smith I, Cherryman G, et al. The value of computed tomography (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. Br J Cancer 1990;62:684-6.
14. Arriagada R, Monnet I, Riviere A, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. Eur J Cancer 1995;31A:Suppl 5:83. abstract.
15. Arriagada R, LeChevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-90.
16. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997;33:1752-8.
17. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-84.
18. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001;1:5.
19. Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol 2006;24:3597-603.
20. Glantz MJ, Choy H, Yee L. Prophylactic cranial irradiation in small cell lung cancer: rationale, results and recommendations. Semin Oncol 1997;24:477-83.
21. van Oosterhout AG, van de Pol M, ten Velde G, Twijnstra A. Neurologic disorders in 203 consecutive patients with small cell lung cancer: results of a longitudinal study. Cancer 1996;77:1434-41.
22. Freedman LS, White SJ. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976;32:691-4.
23. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. Hoboken, NJ: John Wiley & Sons, 2002.
24. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
25. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
26. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801.
27. Kotalik J, Yu E, Markman BR, Evans WK. Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;50:309-16.
28. Suwinski R, Lee SP, Withers HR. Dose-response relationship for prophylactic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;40:797-806.
29. Thatcher N, Faivre-Finn C, Lorigan P. Management of small-cell lung cancer. Ann Oncol 2005;16:Suppl 2:ii235-ii239.
30. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-72.
31. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S. Second-line chemotherapy in recurrent small cell lung cancer: results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEVregimen). Lung Cancer 2005;48:251-61.